Despite the limitation that our proteomic study was performed by overexpressing GEMC1 or MCIDAS in cycling AD-293 cells, our approach is strongly validated by its ability to identify most of the factors known to be involved in MCC transcription and the fact that multiple BRD9 inhibitors impair the MCC pathway. Here, BRD9 is linked to Alzheimer disease.